Bajaj Healthcare Ltd (BSE: 539872) is a Thane, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,096 Cr, it ranks #1,529 by market cap among the 6,197 Indian listed companies on FinBizNet, and #45 of 86 in Medicinal Chemicals and Botanical Products. At ₹323.05 (as of 16 Nov 2026), the share price is 29.5% below its 52-week high of ₹458.00 and 18.6% above its 52-week low of ₹272.35. The share price is down 27.0% over one year and down 2.4% over three months.
| Current Price | ₹323.05 |
|---|---|
| Market Cap | ₹1,096 Cr |
| BSE Code | 539872 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 48.5 |
| Return on Equity | 4.27% |
| Return on Assets | 5.51% |
| 52-Week Range | ₹272.35 – ₹458.00 |
| 1-Year Price Change | -27.0% |
| 3-Month Price Change | -2.4% |
| Beta (1Y) | 0.38 |
| Dividend Yield | 0.46% |
| Headquarters | Thane, Maharashtra |
| Website | www.bajajhealth.com |
| Revenue | ₹176 Cr |
|---|---|
| Net Profit | ₹14 Cr |
| Net Margin | 8.0% |
| EPS (Basic) | ₹4.27 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bajaj Healthcare Ltd reported revenue of ₹176 Cr in Q2 FY27, up 18.9% from ₹148 Cr in Q2 FY26 and up 6.2% from ₹166 Cr in Q1 FY27. It posted a net profit of ₹14 Cr for the quarter, against a net profit of ₹11 Cr in Q2 FY26 (up 26.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹148 Cr (Q2 FY26) to ₹176 Cr (Q2 FY27). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹176 Cr | ₹14 Cr | 8.0% |
| Q1 FY27 | ₹166 Cr | ₹14 Cr | 8.3% |
| Q4 FY26 | ₹153 Cr | −₹23 Cr | −14.9% |
| Q3 FY26 | ₹161 Cr | ₹16 Cr | 9.7% |
| Q2 FY26 | ₹148 Cr | ₹11 Cr | 7.5% |
| Q1 FY26 | ₹149 Cr | ₹12 Cr | 7.9% |
| Q4 FY25 | ₹154 Cr | ₹11 Cr | 7.2% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 58.59% of Bajaj Healthcare Ltd's shares as of Sept 2026, against 59.19% in Sept 2025 (−0.60 percentage points). Delivery averaged 48.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, antihelmintic, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, phlebotropic drug, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl x
1. Pharma-This segment engages in the API and formulation business. 2. Bulk Drugs-This segment manufactures and sells bulk drugs. 3. Formulations-This segment manufactures and markets active pharmaceutical ingredients, intermediates, and finished dosage formulations with focus on vitamins, amino acids, anti-convulsants, and finished dosage forms catering various therapeutic applications. 4. Intersegment Revenue-0
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Bajaj Healthcare Ltd | ₹1,096 Cr | 48.5 | 4.27% | ₹176 Cr | -27.0% |
Listed by market capitalisation. Ratios are shown for context only.
Bajaj Healthcare Ltd is trading at ₹323.05, with a market capitalisation of ₹1,096 Cr.
Bajaj Healthcare Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Bajaj Healthcare Ltd has a P/E of 48.5 and a return on equity of 4.27%.
Bajaj Healthcare Ltd is listed on the BSE under the scrip code 539872.
Bajaj Healthcare Ltd's share price is down 27.0% over one year and down 2.4% over three months. Its 52-week range is ₹272.35 to ₹458.00.
In Q2 FY27, Bajaj Healthcare Ltd reported revenue of ₹176 Cr and net profit of ₹14 Cr, with basic EPS of ₹4.27 (standalone, parsed from the company's exchange filing).
Bajaj Healthcare Ltd reported revenue of ₹176 Cr in Q2 FY27, up 18.9% from ₹148 Cr in Q2 FY26 and up 6.2% from ₹166 Cr in Q1 FY27.
Promoters held 58.59% of Bajaj Healthcare Ltd's shares as of Sept 2026, against 59.19% in Sept 2025 (−0.60 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.